Recce Pharmaceuticals Ltd Stock

Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company’s anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are 100% water soluble at all pH levels in their liquid form.